Study of TV-1106 in Growth Hormone-Deficient Adults
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02410343
- Locations
- 🇬🇷
Teva Investigational Site 63054, Athens, Greece
🇷🇺Teva Investigational Site 50303, Saint-Petersburg, Russian Federation
🇺🇸Teva Investigational Site 13112, Henderson, Nevada, United States
A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT02365636
- Locations
- 🇺🇸
Teva Investigational Site 13053, Atlanta, Georgia, United States
🇺🇸Teva Investigational Site 13064, Miami, Florida, United States
🇺🇸Teva Investigational Site 13335, Miami, Florida, United States
An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT02315144
- Locations
- 🇺🇸
Teva Investigational Site 13038, Medford, Oregon, United States
🇺🇸Teva Investigational Site 13039, Spartanburg, South Carolina, United States
🇦🇺Teva Investigational Site 78993, Daws Park, Australia
Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT02315131
- Locations
- 🇦🇺
Teva Investigational Site 78984, Adelaide, Australia
🇺🇸Teva Investigational Site 13033, Saint Louis, Missouri, United States
🇺🇸Teva Investigational Site 13034, Raleigh, North Carolina, United States
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
- Conditions
- Primary Progressive Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 374
- Registration Number
- NCT02284568
- Locations
- 🇩🇪
Teva Investigational Site 32512, Bamberg, Germany
🇩🇪Teva Investigational Site 32505, Bad Mergentheim, Germany
🇩🇪Teva Investigational Site 32523, Trier, Germany
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 352
- Registration Number
- NCT02215616
- Locations
- 🇨🇦
Teva Investigational Site 11079, Toronto, Ontario, Canada
🇺🇸Teva Investigational Site 12567, San Francisco, California, United States
🇺🇸Teva Investigational Site 12565, Los Angeles, California, United States
Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02215941
- Locations
- 🇺🇸
Teva Investigational Site 12961, Lenexa, Kansas, United States
A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- COPDChronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT02203474
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02190721
- Locations
- 🇷🇴
Teva Investigational Site 52063, Bucharest, Romania
🇺🇸Teva Investigational Site 12957, Houston, Texas, United States
🇭🇺Teva Investigational Site 51186, Budapest, Hungary
Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02184767
- Locations
- 🇺🇸
Teva Investigational Site 12468, Atlanta, Georgia, United States
🇺🇸Teva Investigational Site 12469, Cincinnati, Ohio, United States